Leadership Seminar: Expanding the Druggable Space

In collaboration with.. 

With the increasing limitations of current therapeutics and new healthcare challenges, the need for more innovation is higher than ever, looking at pushing the boundaries of the druggable space.

At the moment only 10% of the druggable genome is currently targeted by FDA approved drugs with 75% of protein research still focusing on these well-known targets. This imply that there is a potential to increase tenfold the therapeutics options on the market. Not even mentioning the rise of technologies such as AI, synthetic biology etc… that can support truly disruptive innovations to be delivered to patients.

This event will review the potential for innovations in the field of gene and cell therapy, oligonucleotides therapeutics and post transcriptional approaches together with discussing the challenges on the way to their adoption in healthcare delivery.

Interested in Exhibiting?  If you would like to find out more then please contact Alicia.

Programme

10.00: Delegates registration

10.30: Welcome from the hosts

♦ Aline Charpentier, One Nucleus

♦ Paul Mercer, The Francis Crick Institute

10.50: Target prioritisation and the druggable genome, Anna Gaulton, EMBL-EBI

11.15: Drugging the Undrugged with Protein Interference, Markus Muellner, PhoreMost

11.40: The CRISPR toolbox and its use in drug development, Victor Dillard, Desktop Genetics

12.05: Start with the end in mind: How to design evidence generation plans to accelerate NICE approval, Jeanetter Kusel, NICE

12.30: Lunch  

13.45: RNA Silencing: A new frontier for therapeutics in rare disease and cardiovascular medicine, David Horn Solomon, Silence Therapeutics

14.10: mRNA as a therapeutic modality, Steven Powell, eTheRNA

14.35: Immunotherapy of solid tumours using CAR T-cells, John Maher, King’s College London

15.00: Coffee break

15.30: RAS Inhibitory Biologics - a Novel Approach to Cancer Therapy, Ralph Minter, AstraZeneca 

15.55: Strategic patenting (in a crowded space), Craig Titmus, Mathys & Squire

16.15: Gene therapy comes of age - but are the payors ready?, Adrian Dawkes, PharmaVentures 

16.35: Closing remarks

16.40: Drinks reception

18.00: End

Costs:

One Nucleus Gold Members: £75 +VAT
One Nucleus Silver Members: £175 +VAT
One Nucleus Non members: £275 +VAT

**This button will not work if you are not logged in**